Nycomed US appoints three

Newly created standalone corporation hires former King Pharmaceuticals executives

Following Takeda Pharmaceuticals’ purchase of Nycomed of Switzerland in May, which excluded Nycomed’s dermatology business in US, the newly created standalone corporation Nycomed US has made three senior appointments.

Nycomed US, which is owned primarily by Nordic Capital, Credit Suisse and Avista Capital Partners, has appointed Brian Markison as president and chief executive and member of the board.

In addition, Jeff Bailey has been hired to the newly created position of chief operating officer, and John Golubieski has joined as chief financial officer.

Nycomed US expects to grow organically as well as through acquisitions, product partnerships and in-licensing opportunities.

The company is based in Melville, NY, with manufacturing facilities in Melville and Hicksville, NY, a distribution centre in Mechanicsburg, PA and the Fougera and PharmaDerm marketing and sales divisions in Melville, NY and Florham Park, NJ.

Markison was formerly chairman and chief executive of King Pharmaceuticals, which he joined as coo before being promoted to president and ceo in 2004 and elected to chairman in 2007. Before this, he held various senior positions at Bristol-Myers Squibb.

Markison is on the board of directors of Immunomedics and Rosetta Genomics, where he also serves as chairman.

Hakan Bjorklund, chief executive of Nycomed and chairman of Nycomed US, said: ‘The board and I have full confidence that Brian's broad experience, stature in the industry and proven record of success make him the right person to lead Nycomed US as it becomes a standalone company and meets the challenges of the future.

‘We are further delighted that Brian already has attracted two industry veterans to add to the depth we have within Nycomed US.’

Markison added: ‘We will look to aggressively expand our offerings by evaluating strategic acquisitions and partnerships to enhance our position as a leading dermatology player in the US.’

Bailey was previously chief commercial officer of King - Pfizer Pharmaceuticals. Earlier, he worked with Novartis Pharmaceuticals as president and general manager, as well as Janssen Pharmaceutica, part of Johnson & Johnson.

Golubieski spent the last six years as senior vice president of financial planning and analysis at King - Pfizer Pharmaceuticals. Previously, he worked for Bristol-Myers Squibb and PriceWaterhouse.

You may also like

Finance

Takeda Pharmaceutical to acquire GammaDelta Therapeutics

Abingworth was the founding investor in GammaDelta and provided initial seed funding as part of the company’s creation in 2016
Finance

Takeda to evaluate Aptamer Group reagents for drug development

Based on oligonucleotide molecules, Optimers (which the company describes as optimised aptamer reagents) can bind specifically to a target molecule to act as an antibody alternative
Finance

Adaptate Biotherapeutics raises $18 m in Series A2 funding

The financing will also support the company’s expansion, including further recruitment and increased laboratory and office space
Finance

Novadiscovery enters clinical simulation collaboration with Takeda

This agreement builds on an existing relationship between the companies that began in 2017
Research & Development

Evox Therapeutics and Takeda sign multitarget rare disease collaboration

Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox’s proprietary exosome technology
Finance

Charles River secures milestone deals with Takeda and HemaCare

The laboratory giant inks deal with global Japanese drugmaker and completes acquisition of the cell and gene products manufacturer
Media

Only a handful of pharma companies are developing the urgently needed new medicines for the poor

The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical companies and on five diseases
Subscribe now